NEW YORK, March 26, 2019 /PRNewswire/ -- Chemotherapy, Targeted Therapy, Cytarabine, Daunorubicin, Midostaurin, EnasidenibRead the full report: https://www.reportlinker.com/p05605443/?utm_source=PRN
The global acute myeloid leukaemia market reached $1bn in 2017 and is estimated to reach $2.8bn by 2022. In 2017, the chemotherapy segment held 69% of the global acute myeloid leukaemia market.How this report will benefit youRead on to discover how you can exploit the future business opportunities emerging in this sector.In this brand new 135-page report you will receive 92 charts– all unavailable elsewhere.The 135-page report provides clear detailed insight into the acute myeloid leukaemia market. Discover the key drivers and challenges affecting the market.By ordering and reading our brand-new report today you stay better informed and ready to act.Report Scope- Global Acute Myeloid Leukaemia Market from 2018-2028Forecast of the Global Acute Myeloid Leukaemia market by Treatment Type and Product Type:- Chemotherapy: Cytarabine, Daunorubicin, Others- Targeted Therapy: Midostaurin, Enasidenib, OthersThis report provides individual revenue forecasts to 2028 for these regional and national markets:- North America: US, Canada, and Mexico- Europe: Germany, France, United Kingdom, Italy, Spain, Russia, and rest of Europe- Asia-Pacific: Japan, China, Australia, South Korea, India, and rest of Asia-Pacific- LAMEA: Brazil, Saudi Arabia, Republic of South Africa, Turkey, and rest of LAMEAOur study discusses the selected leading companies that are the major players in the acute myeloid leukaemia market:- Bristol-Myers Squibb Company- Celgene- Clavis Pharma ASA- Daiichi Sankyo- Eisai- GSK- Novartis- Roche- Sunesis Pharmaceuticals- Teva- This report discusses factors that drive and restrain the acute myeloid leukaemia market. This report also discusses the opportunities that can be tapped in this market.- This report also discusses several new agents that are in development for the treatment of acute myeloid leukaemia.Read the full report: https://www.reportlinker.com/p05605443/?utm_source=PRN
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ Contact Clare: [email protected]
US: (339)-368-6001 Intl: +1 339-368-6001
Advertisement
View original content:http://www.prnewswire.com/news-releases/the-global-acute-myeloid-leukaemia-market-reached-1bn-in-2017-and-is-estimated-to-reach-2-8bn-by-2022--300818794.html
SOURCE Reportlinker
